World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder

Bauer, Michael; Whybrow, Peter C.; Angst, Jules; Versiani, Márcio; Möller, Hans‐Jürgen

doi:10.3109/15622970209150599

Cited by 339 publications

(189 citation statements)

References 280 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…21 Response was defined as a decrease in HDRS of more than 50%, according to the World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. 22 The number of responders in dependence of genotypes was calculated as secondary response parameter.…”

Section: Discussionmentioning

confidence: 99%

A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment

et al. 2006

View full text Add to dashboard Cite

Finding predictors of the response to antidepressant therapy is a major goal of molecular psychiatry. The genes encoding the serotonin (SERT) and dopamine (DAT1) transporters are among the possible candidate genes modulating an individual's antidepressant response. In a naturalistic prospective cohort study with a total of 190 fully assessed patients, improvement of depression symptoms during the 3 weeks following initiation of antidepressant therapy was recorded using the 21-item Hamilton Depression Rating Scale (HDRS). The SLC6A3 3 0 UTR 40-bp variable number of tandem repeats (VNTR) and the SLC6A4 5 0 44-bp insertion/deletion polymorphism were analyzed by polymerase chain reaction. There was a significantly smaller number of rapid responders among homozygous carriers of the DAT1 9-repeat allele (9/9) than among heterozygous (9/10) and homozygous (10/10) carriers of the 10-repeat allele (19 versus 37 versus 52%, respectively, P ¼ 0.0037). Median decline in HDRS score was 35, 40, and 52% in patients with the 9/9, 9/10, and 10/10 genotypes, respectively (P ¼ 0.013). The effect was found in all classes of medications (selective serotonin reuptake inhibitors (SSRIs), tricyclics, mirtazapine, venlafaxine) and statistically significant also within the subgroup of patients having received SSRIs. The serotonin promoter insertion/deletion genotype had no effect in the entire study group, but there was an insignificant trend of better response in the l/l and l/s carriers who received SSRIs or mirtazapine. In conclusion, the dopamine transporter VNTR polymorphism influenced rapid response to antidepressant therapy. Compared with homozygous carriers of the 10-repeat allele, carriers of the 9/10 genotype had an odds ratio (OR) calculated by logistic regression analysis of 1.6 (95% CI 0.8-3.2) and carriers of the 9/9 genotype had an OR of 6.0 (1.5-24.4) for no or poor response. Further studies are required to confirm this clinical association and to elucidate the underlying mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%

A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment

et al. 2006

View full text Add to dashboard Cite

show abstract

“…According to the evidence, about 30% of all depression patients do not respond sufficiently to the first antidepressant drug given. 4,5 Failure to respond to antidepressant drug therapy as well as intolerable side effects not only determine personal suffering of individuals and their families, but also impose considerable costs on society. At present, there is no possibility to reliably predict the individual's response before onset of a certain drug treatment.…”

Section: Depressionmentioning

confidence: 99%

The clinical role of genetic polymorphisms in drug-metabolizing enzymes

et al. 2007

View full text Add to dashboard Cite

“…However, a direct relationship between serum levels and clinical response, as well as administered dose and clinical response, has not been observed for SSRIs but this is controversial. [64][65][66][67][68] To develop the investigation of antidepressant response in a clinical trial, a washout period from all previous treatment is necessary, but this could be a serious challenge in acutely ill patients. In fact from one side, if symptoms exacerbation occurs, this could complicate baseline setup, as well as it add ethical concerns and management issues.…”

Section: Treatment Issuesmentioning

confidence: 99%

Pharmacogenetic studies in depression: a proposal for methodologic guidelines

2007

View full text Add to dashboard Cite

Pharmacogenetic studies in mood disorders are rapidly proliferating after the initial reports linking gene variants to treatment outcomes. However, a considerable range of methodologies has been used, making it difficult to compare results across studies and limiting the representativeness of findings. Specification of sampling source (inpatients vs outpatients, primary vs tertiary settings), standardization of diagnostic systems and treatments, adequate monitoring of compliance through plasma levels, sufficient length of observation (at least 6 weeks for acute antidepressant treatments, though 3-6 months are preferable), the use of a range of response criteria and the inclusion of possible environmental confounding variables (life events, social support, temperament) are all potentially important issues when planning pharmacogenetic studies. We reviewed the state-of-the-art methodology and suggested possible guideline for future studies.

show abstract

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder

Cited by 339 publications

References 280 publications

A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment

A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment

The clinical role of genetic polymorphisms in drug-metabolizing enzymes

Pharmacogenetic studies in depression: a proposal for methodologic guidelines

Contact Info

Product

Resources

About